Markus from Austria

Registered at the short selling broker Capital, 2 minutes ago.

» Try Capital you too
67.7% of retail investor accounts lose money when trading CFDs with Capital.
Don't show again

Sanofi (SNY) shares information

Sanofi – ADR


24h Change

0.78 %

SNY

Live rate: Market closed

Stock data per Friday 25 Nov, 2022

SNY
NASDAQ
45.04
45.16
45.39
0.35 (+ 0.78%)
US Market is closed

Live Stock price in graph for Sanofi – ADR (SNY)

  • Latest Volume

    686,616 (-74.85 %)

  • Volume prev. day

    2,730,361

  • Avg. daily volume

    2,643,220

  • Market cap

    115,061,754,241

  • P/E ratio

    16.21

  • Today high

    45.62 USD

  • Today low

    45.16 USD

  • 52 week high

    56.2 USD

  • 52 week low

    36.91 USD

  • YTD Change

    n/a

Quick links

 

Latest news about Sanofi – ADR

Below you can find the most recent news posts about Sanofi – ADR, primarily from US and UK based news sources.

What”s next for Zach Wilson and the Jets?

Wednesday, 23 November 2022, 18:17:56

— Kwhen Finance


Sanofi”s Enjaymo for hemolytic anemia given marketing authorization by EC

Friday, 18 November 2022, 16:21:39
Sanofi’s Enjaymo for hemolytic anemia in adult patients with CAD has been granted marketing authorization by the European Commission (EC).
— Labiotech


With Sanofi as its marketing partner, Provention Bio grabs long-awaited FDA nod for diabetes drug

Friday, 18 November 2022, 16:21:23
With Sanofi as its marketing partner, Provention Bio grabs long-awaited FDA nod for diabetes drug kdunleavy Fri, 11/18/2022 – 10:21
— FiercePharma


Provention gets FDA nod on drug to delay type I diabetes, kicking off US launch with Sanofi

Friday, 18 November 2022, 13:17:04
For the first time, the FDA has approved a drug to delay the onset of type I diabetes, potentially giving children, teenagers and young adults more time before needing to take insulin. Provention Bio won FDA approval on Thursday for its drug teplizumab — and, per a recent deal, it
— Endpoints News


Lilly”s interchangeable insulin biosimilar to Sanofi”s Lantus gets FDA approval

Friday, 18 November 2022, 13:04:31
The U.S. Food and Drug Administration approved Eli Lilly”s (LLY) interchangeable biosimilar insulin Rezvoglar (insulin glargine-aglr).This is the second interchangeable biosimilar…
— Seeking Alpha


Trading broker recommendation

We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €250 by bank
Description: Capital.com offer a large number of stocks for trading. Register an account today and check if they have SNY available or trade one of the many other CFD stocks they have.
Risk warning: 67.7% of retail investor accounts lose money when trading CFDs with Capital.